Kosan Initiates Phase 2 Trial Of Epothilone KOS-1584 In Non-Small Cell Lung Cancer

Kosan Biosciences Incorporated (Nasdaq: KOSN) announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated.

Karmanos Researchers Study The Impact Of Galectin-3 On Breast Cancer Disparity In Caucasian And Asian Women

Researchers at the Barbara Ann Karmanos Cancer Institute in Detroit have been studying racial disparities related to cancer patients. Today, at the American Association for Cancer Research (AACR) Annual Meeting, Karmanos researchers Vitaly Balan, Ph.

Additive Anti-Tumor Activity Of NKTR-102 In Combination With Bevacizumab Highlighted In Positive Preclinical Data Presented At AACR Meeting

Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal cancer when co-administered with bevacizumab.

New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit

Systems Medicine LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study identifying the genetic markers in patients more likely to respond to treatment with the experimental drug, brostallicin, at the 2008 American Association for Cancer Research (AACR) annual meeting.

CDC Urges Travelers To Israel To Protect Themselves From Measles

As Americans travel to Israel for the Jewish holiday of Passover, the Centers for Disease Control and Prevention advises all travelers to ensure they are protected from measles before departing, because of a measles outbreak in Israel.

Perrigo Announces Approval For Over The Counter Children's Cetirizine Oral Solution

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Children's Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1mg/mL.

Texas Heart R Institute At St. Luke's Episcopal Hospital Initiates First Clinical Trial To Treat A Heart Attack Patient With A Special Stem Cell

Physician scientists at the Texas Heart Institute (THI) at St. Luke's Episcopal Hospital announced they have begun the world's first clinical trial to treat heart attack patients with a special type of stem cell to promote better healing and to prevent congestive heart failure, which many patients develop following a heart attack.

Infection Experts' Report Reveals The CDC'S Deadly Mistakes

On Wednesday, April 16th the House Committee on Government Oversight and Reform will hold a hearing on whether the federal government is doing enough to prevent hospital infections. The answer is no.

Boston Scientific Announces Japanese Approval Of Heart Failure Lead

Boston Scientific Corporation (NYSE: BSX) announced Japanese Ministry of Health, Labor and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular lead for use with cardiac resynchronization therapy (CRT) devices, which treat heart failure.

Genzyme Genetics Announces Launch Of Carrier Testing And Prenatal Diagnosis For Spinal Muscular Atrophy

Genzyme Genetics, a business unit of Genzyme Corporation (Nasdaq: GENZ), announced that it is the first national laboratory specializing in reproductive testing to provide population carrier and prenatal diagnostic testing for spinal muscular atrophy (SMA), the most common inherited cause of infant mortality.